These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Treatment of pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) with weight-based anakinra dosing in a Hepatitis B carrier. Jennings L; Molloy O; Quinlan C; Kelly G; O'Kane M Int J Dermatol; 2017 Jun; 56(6):e128-e129. PubMed ID: 28239847 [No Abstract] [Full Text] [Related]
10. Long-term Remission of Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome. Brokamp G; Bechtel M; Chung C Cutis; 2023 Jun; 111(6):E2-E6. PubMed ID: 37487120 [TBL] [Abstract][Full Text] [Related]
11. Remission of refractory pyoderma gangrenosum, severe acne, and hidradenitis suppurativa (PASH) syndrome using targeted antibiotic therapy in 4 patients. Join-Lambert O; Duchatelet S; Delage M; Miskinyte S; Coignard H; Lemarchand N; Alemy-Carreau M; Lortholary O; Nassif X; Hovnanian A; Nassif A J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S66-9. PubMed ID: 26470620 [TBL] [Abstract][Full Text] [Related]
12. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition. Saraceno R; Babino G; Chiricozzi A; Zangrilli A; Chimenti S J Am Acad Dermatol; 2015 Jan; 72(1):e42-4. PubMed ID: 25497954 [No Abstract] [Full Text] [Related]
13. Pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis (PAPASH)-syndrome: a new entity within the spectrum of autoinflammatory syndromes? Garzorz N; Papanagiotou V; Atenhan A; Andres C; Eyerich S; Eyerich K; Ring J; Brockow K J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):141-3. PubMed ID: 25070077 [No Abstract] [Full Text] [Related]
14. Novel PSTPIP1 gene mutation in pyoderma gangrenosum, acne and suppurative hidradenitis syndrome. Saito N; Minami-Hori M; Nagahata H; Nozaki H; Iinuma S; Igawa S; Kanno K; Kishibe M; Kanazawa N; Ishida-Yamamoto A J Dermatol; 2018 Aug; 45(8):e213-e214. PubMed ID: 29575118 [No Abstract] [Full Text] [Related]
15. Remission of Refractory PASH Syndrome Using Ixekizumab and Doxycycline. Gul MI; Singam V; Hanson C; Neill BC; Aires DJ; Rajpara AN J Drugs Dermatol; 2020 Nov; 19(11):1123. PubMed ID: 33196740 [No Abstract] [Full Text] [Related]
16. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone. Staub J; Pfannschmidt N; Strohal R; Braun-Falco M; Lohse P; Goerdt S; Leverkus M J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2243-7. PubMed ID: 25352307 [TBL] [Abstract][Full Text] [Related]
17. Tildrakizumab in the treatment of PASH syndrome: A potential novel therapeutic target. Kok Y; Nicolopoulos J; Varigos G; Howard A; Dolianitis C Australas J Dermatol; 2020 Aug; 61(3):e373-e374. PubMed ID: 32285437 [No Abstract] [Full Text] [Related]
18. Pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) and polycystic ovary syndrome: Coincidentally or aetiologically connected? Zivanovic D; Masirevic I; Ruzicka T; Braun-Falco M; Nikolic M Australas J Dermatol; 2017 May; 58(2):e54-e59. PubMed ID: 26831949 [TBL] [Abstract][Full Text] [Related]
19. Secukinumab for PASS syndrome: A new choice for therapeutic challenge? Li M; Xiang H; Liang Y; Xue L; Zhou X; Yang L; Liu H; Yang M; Tang J; Li W Dermatol Ther; 2022 Jul; 35(7):e15507. PubMed ID: 35419914 [TBL] [Abstract][Full Text] [Related]
20. Successful treatment of PASS syndrome with IVIG and anti-IL-1 treatment: A case report. Kırmızıer G; Kılınç EA; Yıldırım NO; Türsen Ü Int J Rheum Dis; 2024 Mar; 27(3):e15114. PubMed ID: 38465508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]